CAS Number71125-38-7
SynonymsMeloxicam; Metacam; Parocin; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide; Meloxciam; 4-hydroxy-2-méthyl-N-(5-méthyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxyde; 2H-1,2-Benzothiazine-3-carboximidic acid, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide; Movatec; 4-Hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; meloxicam (tautomer); MOBIC; Mobicox; MFCD11046047; Movalis; MOBEC
Molecular FormulaC14H13N3O4S2
Molecular Weight351.40
Purity98.00%
Density1.6±0.1 g/cm3
Boiling Point581.3±60.0 °C at 760 mmHg
Melting Point255ºC
AppearanceLight yellow solid
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 71125-38-7 |
| Catalog No. | 2A-9011329 |
| Chinese Name | 美洛昔康 |
| Synonyms | Meloxicam; Metacam; Parocin; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide; Meloxciam; 4-hydroxy-2-méthyl-N-(5-méthyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxyde; 2H-1,2-Benzothiazine-3-carboximidic acid, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide; Movatec; 4-Hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; meloxicam (tautomer); MOBIC; Mobicox; MFCD11046047; Movalis; MOBEC |
| Molecular Formula | C14H13N3O4S2 |
| Molecular Weight | 351.40 |
| Purity | 98.00 |
| Density | 1.6±0.1 g/cm3 |
| Boiling Point | 581.3±60.0 °C at 760 mmHg |
| Melting Point | 255ºC |
| Appearance | Light yellow solid |
| Water Solubility | DMSO: soluble |
| Storage Condition | Store in a sealed container in a cool, dry place. |
| Packaging | III |
| Application | Meloxicam is a non-steroidal anti-inflammatory agent that can effectively inhibit the activity of COX, with IC50 values of 0.49 µM and 36.6 µM for COX-2 and COX-1 respectively. |
| HTC | 2934999090 |
| SMILES | Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1 |
| InChI | 1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,19H,1-2H3,(H,15,16)/b13-11+ |
| InChI Key | DWMREKMVXIFPFM-ACCUITESSA-N |
| NACRES Code | NA.24 |
| UNSPSC | 41116107 |
| MSDS | msds/11329_1_71125_38_7.pdf |
| Bioactivity | Meloxicam is a non-steroidal antiinflammatory agent, inhibits COX activity, with IC50s of 0.49 µM and 36.6 µM for COX-2 and COX-1, respectively. Related Catalog Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Immunology/Inflammation >> COX Research Areas >> Inflammation/Immunology Target COX-2:0.49 μM (IC50) COX-1:36.6 μM (IC50) In Vitro Meloxicam (Compound 5) is a non-steroidal antiinflammatory agent, inhibits COX activity, with IC50s of 0.49 µM and 36.6 µM for COX-2 and COX-1, respectively[1]. Meloxicam inhibits COX+ tumor cells, but shows no cytotoxicity on CF41.Mg or MDCK cells at 0.25-25 µg/mL. Furthermore, Meloxicam in combination with doxorubicin, has no synergistic effect on CF41.Mg cells. Meloxicam (0.25 µg/mL) decreases CF41.Mg cell migration and invasion, induces decrease in MMP-2 expression, and increases β-catenin phophorylation in CF41.Mg cells, but does not affect the CF41.Mg cell apoptosis[2]. In Vivo Meloxicam (10 mg/kg) alone or in combination with rutin significantly decreases paw liking time on 1st day by 55% and 49% compared with the formalin-treated group, respectively, however the combination reduces time non-significantly on 3rd day in mice. Meloxicam alone or in combination with rutin also decreases relative liver weights, reduces MDA contents, induces liver SOD activities, hampers IL-1β content, and significantly reduces the number of positive caspase-3 immunoreactive cells in mice[3]. Cell Assay CF41.Mg and MDCK cells are seeded at a density of 1.5 × 103 cells/well into 96-well plates, cultured for 24 h and then exposed to 0-25 µg/mL Meloxicam alone or in combination with doxorubicin. To evaluate synergism and sensitization, doxorubicin is added at the same time and after 24 h, respectively. MDCK cells are exposed only to Meloxicam as a non-tumor negative control. Control groups are cultured without Meloxicam and doxorubicin, but the corresponding amount of DMSO is added to the medium. Following an incubation period of 24 and 48 h, cell growth is measured using the MTS assay, with the absorbance at 490 nm determined using a microplate reader. Each experiment is performed 3 times in triplicate[2]. Animal Admin Mice[3] Thirty-two mice are randomLy allocated into four groups, eight mice each. Groups are received 20 μL of 2.5% formalin injected in the plantar region of the right hind paw of mice on the 1st and 3rd days 1 h after administration of 1% DMSO (group 1; positive control group), 60 mg/kg rutin, orally (group 2), and oral treatment with 10 mg/kg Meloxicam (group 3), as well as combined treatment of rutin and Meloxicam (group 4). In all groups, drugs are administered once a day for duration of 7 days. On day 7, mice are euthanized and right hind paws plus livers are immediately excised, washed with ice-cold saline, blotted dry, and weighed. They are stored at −80°C till the time of analysis. Then the used animals will be frozen till being incinerated[3]. References [1]. Lazer ES, et al. Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity. J Med Chem. 1997 Mar 14;40(6):980-9. [2]. Iturriaga MP, et al. Meloxicam decreases the migration and invasion of CF41.Mg canine mammary carcinoma cells. Oncol Lett. 2017 Aug;14(2):2198-2206. [3]. Fikry EM, et al. Rutin and meloxicam attenuate paw inflammation in mice: Affecting sorbitol dehydrogenase activity. J Biochem Mol Toxicol. 2018 Feb;32(2). Chemical & Physical Properties Density 1.6±0.1 g/cm3 Boiling Point 581.3±60.0 °C at 760 mmHg Melting Point 255ºC Molecular Formula C14H13N3O4S2 Molecular Weight 351.401 Flash Point 305.4±32.9 °C Exact Mass 351.034760 PSA 136.22000 LogP 3.35 Vapour Pressure 0.0±1.7 mmHg at 25°C Index of Refraction 1.735 InChIKey ZRVUJXDFFKFLMG-UHFFFAOYSA-N SMILES Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1 Water Solubility DMSO: soluble |
| Use of | Meloxicam is a non-steroidal antiinflammatory agent, inhibits COX activity, with IC50s of 0.49 µM and 36.6 µM for COX-2 and COX-1, respectively. Properties Articles55 Name meloxicam Synonym More Synonyms Meloxicam Biological Activity Description Meloxicam is a non-steroidal antiinflammatory agent, inhibits COX activity, with IC50s of 0.49 µM and 36.6 µM for COX-2 and COX-1, respectively. Related Catalog Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Immunology/Inflammation >> COX Research Areas >> Inflammation/Immunology COX-2:0.49 μM (IC50) COX-1:36.6 μM (IC50) In Vitro Meloxicam (Compound 5) is a non-steroidal antiinflammatory agent, inhibits COX activity, with IC50s of 0.49 µM and 36.6 µM for COX-2 and COX-1, respectively[1]. Meloxicam inhibits COX+ tumor cells, but shows no cytotoxicity on CF41.Mg or MDCK cells at 0.25-25 µg/mL. Furthermore, Meloxicam in combination with doxorubicin, has no synergistic effect on CF41.Mg cells. Meloxicam (0.25 µg/mL) decreases CF41.Mg cell migration and invasion, induces decrease in MMP-2 expression, and increases β-catenin phophorylation in CF41.Mg cells, but does not affect the CF41.Mg cell apoptosis[2]. References [2]. Iturriaga MP, et al. Meloxicam decreases the migration and invasion of CF41.Mg canine mammary carcinoma cells. Oncol Lett. 2017 Aug;14(2):2198-2206. [3]. Fikry EM, et al. Rutin and meloxicam attenuate paw inflammation in mice: Affecting sorbitol dehydrogenase activity. J Biochem Mol Toxicol. 2018 Feb;32(2). Chemical & Physical Properties Molecular Formula C14H13N3O4S2 Exact Mass 351.034760 PSA 136.22000 Index of Refraction 1.735 InChIKey ZRVUJXDFFKFLMG-UHFFFAOYSA-N Water Solubility DMSO: soluble |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information United Nations classification: Item 1 Poisons. UN number: 2811 Proper Shipping Name: Toxic Solid, Organic, Not Otherwise Specified Packing grade: III |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Lopinavir | 192725-17-0 | 2A-9011228 |
| Losartan | 114798-26-4 | 2A-9011236 |
| Losartan Potassium | 124750-99-8 | 2A-0200254 |
| Marbofloxacin | 115550-35-1 | 2A-9011292 |
| Mefloquine | 53230-10-7 | 2A-9011319 |
| Melphalan | 148-82-3 | 2A-9011330 |
| Meropenem | 96036-03-2 | 2A-9011349 |
| Meropenem | 119478-56-7 | 2A-9011350 |
| Methotrexate | 51865-79-3 | 2A-9011384 |
| Methotrexate | 91431-42-4 | 2A-9011385 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS